The ingredient in Wegovy and Ozempic
Semaglutide: cost, side effects and semaglutide vs tirzepatide
Semaglutide is the active ingredient in Wegovy, which is FDA-approved for weight management, and in Ozempic, which is FDA-approved for type 2 diabetes and not for weight loss.1,2 This page covers the trial results, semaglutide side effects, semaglutide cost, and how semaglutide vs tirzepatide turned out when the two were tested against each other. A licensed FitRx provider can review your health history online and tell you whether any form is appropriate for you.
- Wegovy: FDA-approved for weight management. Ozempic: for type 2 diabetes, not weight loss
- Compounded semaglutide from $151 a month with a 3-month supply. Not FDA-approved, and not a generic
- A U.S.-licensed provider reads your intake, typically within 1 to 2 business days
FitRx membership costs $39 in month one and $135 a month from then on. Medication is a separate charge. The vial pictured is compounded semaglutide. It is not FDA-approved: the FDA does not review compounded drugs for safety, effectiveness or quality. A provider decides whether to prescribe, and not everyone qualifies. Read the important safety information, which includes a boxed warning.

What the Wegovy trials found
Adults on semaglutide 2.4 mg lost an average of 14.9% of their body weight in the main trial
STEP 1 enrolled adults with overweight or obesity who did not have diabetes, and compared a weekly 2.4 mg semaglutide injection with a placebo for 68 weeks.3 Average weight loss was 14.9% with semaglutide and 2.4% with placebo, from an average starting weight of about 232 pounds. On semaglutide, 83.5% of adults lost at least 5% of their weight and 30.2% lost 20% or more.1
Over two years. In STEP 5, average weight loss at 104 weeks was 15.2% with semaglutide and 2.6% with placebo.4
At a higher dose. STEP UP tested 7.2 mg a week in adults with obesity. At 72 weeks, average weight loss was 18.8% on 7.2 mg, 15.5% on 2.4 mg and 3.9% on placebo.1,5
These trials tested brand-name semaglutide, the medication sold as Wegovy. Compounded semaglutide was not tested in any of them and is not FDA-approved, so the results cannot be assumed to apply to it. They are also averages: some people lost more, some less. The slider applies the STEP 1 averages to a starting weight.
Three forms of semaglutide: Wegovy, Ozempic and compounded
Semaglutide is a GLP-1 receptor agonist: it acts on the receptor for GLP-1, a hormone your gut releases after you eat.6 You will come across it under three names. They are not interchangeable, and only two of them have been through FDA review.
FDA-approved for weight management
Wegovy
Novo Nordisk’s semaglutide for weight management, as a weekly injection or a daily tablet.1
- For adults with obesity, or with overweight and at least one weight-related condition
- Also approved to lower cardiovascular risk in adults with established cardiovascular disease and obesity or overweight
- The medication tested in the STEP trials
FDA-approved for type 2 diabetes
Ozempic
Novo Nordisk’s weekly semaglutide injection for type 2 diabetes, with maintenance doses of 0.5 mg, 1 mg or 2 mg.2
- Improves blood sugar control in adults with type 2 diabetes, alongside diet and exercise
- Not FDA-approved for weight loss
- Ozempic tablets are a separate product, also for type 2 diabetes only7
Not FDA-approved
Compounded semaglutide
A state-licensed compounding pharmacy makes it to fill an individual prescription. The FitRx price starts at $151 a month with a 3-month supply (as of November 18, 2026; prices can change), and membership is extra.
- Not reviewed by the FDA for safety, effectiveness or quality
- Is not a generic of Wegovy or Ozempic and was never part of their trials
- A provider has to decide it is appropriate before it is prescribed
The FDA’s position, in its own words. “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”8 The section on compounded semaglutide goes through the agency’s specific concerns.
The tablets
Wegovy tablets are taken once a day: 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, then 25 mg. The label says to take one in the morning on an empty stomach with up to 4 ounces of plain water, at least 30 minutes before food, drink or other oral medicines. In the 64-week OASIS 4 trial, average weight loss on the 25 mg tablet was 13.6%, compared with 2.4% on placebo.1
How getting semaglutide through FitRx works
Complete the intake
Answer questions online about your health history, the medications you take and what you want from treatment.
A provider reads it
A U.S.-licensed physician or nurse practitioner reviews your answers, typically within 1 to 2 business days, and decides whether semaglutide is appropriate. Sometimes the answer is no.
The prescription goes out
If medication is appropriate, the prescription is sent to a partner pharmacy. For Wegovy or Ozempic, FitRx submits a prior authorization when a commercial plan asks for one.
Care continues
Semaglutide starts at a low dose and steps up. You have monthly video or phone visits and can message your provider in between.
Wegovy’s weight management use is for adults with obesity (a BMI of 30 or higher) and adults with overweight (a BMI of 27 or higher) who have at least one weight-related condition.1 The BMI calculator works out your number from your height and weight. FitRx treats adults 18 and older, and your provider makes the final call. They may recommend a different medication, or none.
FitRx membership: the care around your prescription
Wegovy’s label pairs it with a reduced-calorie diet and more physical activity.1 Membership is the care around it.
Your provider
Review of your intake, any prescription, unlimited secure messaging, and monthly video or phone visits.
Coach and coordinator
A dedicated coach, plus a care coordinator you can message about the practical side of treatment.
Insurance coordination
For brand-name GLP-1 medications, a team sends prior authorizations to commercial plans and can resubmit after a denial.
The price. $39 for the first month and $135 a month after that, charged monthly. Quarterly, semi-annual and annual plans are discounted, and HSA and FSA cards are accepted. You can cancel in the patient portal whenever you like. A membership cannot be paused.
Not included: the medication. Wegovy and Ozempic are paid for at the pharmacy, at a copay or cash price that FitRx does not set. Compounded semaglutide is billed on top of membership, or together with provider care in a bundled plan (see cost). It is not FDA-approved, is not reviewed by the FDA for safety, effectiveness or quality, and is not a generic of either brand. FitRx does not work with government insurance: Medicare, Medicaid or TRICARE.
Semaglutide side effects: what the trials recorded and when to get help
Semaglutide side effects are mostly digestive. Nausea, diarrhea, vomiting, constipation and abdominal pain lead the list on both the Wegovy and the Ozempic label.1,2
| Side effect | Placebo | Wegovy 2.4 mg |
|---|---|---|
| Nausea | 16% | 44% |
| Diarrhea | 16% | 30% |
| Vomiting | 6% | 24% |
| Constipation | 11% | 24% |
| Abdominal pain | 10% | 20% |
| Headache | 10% | 14% |
| Fatigue | 5% | 11% |
| Indigestion | 3% | 9% |
| Dizziness | 4% | 8% |
| Hair loss | 1% | 3% |
Share of adults reporting each reaction with the Wegovy 2.4 mg injection (2,116 adults) or placebo (1,261 adults), from the Wegovy prescribing information.1
Ozempic’s label, at lower doses and in people with type 2 diabetes, shows lower rates: nausea in 15.8% of people on 0.5 mg and 20.3% on 1 mg, compared with 6.1% on placebo.2 The trials differ, so this is not a brand-against-brand comparison.
Dose and timing
Stomach side effects follow the dose. On Ozempic’s label, most of the nausea, vomiting and diarrhea happened while the dose was still being raised.2 In the trial of Wegovy 7.2 mg, nausea was reported by 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo, and altered skin sensation (dysesthesia) by 22%, 6% and 0%.1
This is why the Wegovy injection starts at 0.25 mg and steps up every 4 weeks through 0.5 mg, 1 mg and 1.7 mg, reaching a maintenance dose of 2.4 mg or 1.7 mg from week 17. If a step is hard to tolerate, the label tells prescribers to consider delaying the next increase by 4 weeks.1 Ozempic follows its own schedule, set out in the Ozempic dosage guide. Keep drinking when you have nausea, vomiting or diarrhea: dehydration is how the kidney injury listed on the labels comes about.
Serious risks and their warning signs
- Thyroid C-cell tumors. Wegovy and Ozempic carry a boxed warning because semaglutide caused these tumors in rodents. Whether it does so in people is not known. Report a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
- Pancreatitis. Severe pain in the stomach area that does not go away, with or without vomiting, sometimes felt in the back.
- Gallbladder problems. Pain in the upper stomach, fever, yellowing of the skin or eyes, or clay-colored stools. Gallstones were reported in 1.6% of people on the Wegovy injection and 0.7% on placebo.1
- Other label warnings. Kidney injury when vomiting or diarrhea leaves you dehydrated, serious allergic reactions, low blood sugar if you also take insulin or a sulfonylurea, diabetic eye complications in people with type 2 diabetes, and, on the Wegovy label, a faster heart rate.
- Anesthesia. The labels warn of pulmonary aspiration during general anesthesia or deep sedation. Mention semaglutide to whoever is planning your procedure.
These rates were measured with the brand-name products. Compounded semaglutide is not FDA-approved, is not reviewed by the FDA for safety, effectiveness or quality, and is not a generic of Wegovy or Ozempic, so there are no matching trial figures for it.8
What happens after stopping
In an extension of STEP 1, researchers followed participants for a year after semaglutide was withdrawn. They had lost 17.3% of their weight on the medication. One year after stopping they had regained 11.6 percentage points of it, leaving a net loss of 5.6% at week 120.9 If you are thinking about stopping, plan it with your provider first.
The important safety information has the fuller list, and our GLP-1 side effects guide looks at the whole drug class.
Semaglutide vs tirzepatide: the head-to-head result and the trade-offs
Semaglutide acts on one hormone receptor, GLP-1. Tirzepatide acts on two, GIP and GLP-1. Tirzepatide is sold as Zepbound, which is FDA-approved for weight management and for moderate to severe obstructive sleep apnea in adults with obesity, and as Mounjaro, which is approved for type 2 diabetes and not for weight loss.10,11 Our tirzepatide page covers that ingredient.
SURMOUNT-5: the direct comparison
SURMOUNT-5 compared the two in 751 adults who had obesity and did not have diabetes. Each person took the highest dose they could tolerate. At 72 weeks the tirzepatide group had lost an average of 20.2% of their body weight and the semaglutide group 13.7%. Waist size was down by an average of 18.4 cm and 13.0 cm. Most adverse events were gastrointestinal, mild to moderate, and came mainly during dose escalation.12
What the average leaves out
A larger average does not settle which one is right for you. Wegovy is approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. In SELECT, which followed 17,604 people for about 3 years, such an event occurred in 6.5% of people on semaglutide and 8.0% on placebo (hazard ratio 0.80), and death from any cause in 4.3% and 5.2%.1,13 For the two diabetes brands, see Mounjaro vs. Ozempic.
| Question | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Brand approved for weight management | Wegovy | Zepbound |
| Brand for type 2 diabetes (not approved for weight loss) | Ozempic | Mounjaro |
| Average weight loss in SURMOUNT-5 | 13.7% at 72 weeks | 20.2% at 72 weeks |
| Weekly maintenance dose for weight | 2.4 mg or 1.7 mg; up to 7.2 mg for some adults | 5 mg, 10 mg or 15 mg |
| Tablet form | Yes: Wegovy tablets | Zepbound and Mounjaro are injections |
| Compounded, through FitRx | From $151 a month with a 3-month supply | From $216 a month with a 3-month supply |
Approvals and doses are for the brand-name products.1,10 FitRx prices are as of November 18, 2026 and can change, so confirm them before you start. Compounded semaglutide and compounded tirzepatide are not FDA-approved, are not reviewed by the FDA for safety, effectiveness or quality, are not generics of the brands, and were not tested in SURMOUNT-5.
It is one or the other: Zepbound’s label says tirzepatide is not recommended together with any GLP-1 receptor agonist, and semaglutide is one.10 Your provider can weigh your health history, your insurance and how you tolerate each drug.
Semaglutide cost: list prices, $25 offers, cash prices and FitRx prices
Semaglutide cost depends on which form you are prescribed and who is paying. Novo Nordisk’s list price is $1,349.02 per package of Wegovy (pen, HD pen or pill) and $1,027.51 per Ozempic pen at any strength. Every figure here is as published on November 18, 2026.14,15
| Your route | What you could pay | Limits and conditions |
|---|---|---|
| Wegovy or Ozempic, with commercial insurance that covers it | As little as $25 a month | Novo Nordisk savings offer for each brand. It takes off up to $100 a month; for Ozempic, for up to 48 months. People with government coverage are excluded. |
| Wegovy pen, paying cash | $199 a month for a new patient’s first 2 fills of 0.25 mg or 0.5 mg. Then $349 a month for 0.25 mg through 2.4 mg, or $399 for Wegovy HD 7.2 mg. | NovoCare home delivery or participating pharmacies. The $199 offer runs through December 31, 2026. Needles included. |
| Wegovy pill, paying cash | $149 a month for 1.5 mg, $199 for 4 mg, $299 for 9 mg or 25 mg | One bottle of 30 tablets. |
| Ozempic pen, paying cash | $199 a month for a new patient’s first 2 fills of 0.25 mg or 0.5 mg. Then $349 a month for 0.25 mg, 0.5 mg or 1 mg, or $499 for 2 mg. | Same December 31, 2026 end date. One pen a month. Ozempic is approved for type 2 diabetes, not weight loss. |
| Compounded semaglutide through FitRx | From $151 a month with a 3-month supply, plus membership. Or bundled with provider care: $217 the first month, then $297 a month. | Not FDA-approved. Shipping included. |
| Medicare Part D | $50 a month for Wegovy under the Medicare GLP-1 Bridge, if you qualify | A federal program that runs through December 31, 2027. FitRx cannot process it. |
Sources: Novo Nordisk’s NovoCare and Ozempic pages, and Medicare.14,15,16,17 Prices and offer terms change. Confirm them with Novo Nordisk, your pharmacy or FitRx before you fill.
What the $25 offers require
The $25 figure applies to one group: people with commercial insurance whose plan already covers the brand they were prescribed. Coverage often depends on a prior authorization. FitRx’s insurance coordination team submits those. Plans usually answer within 2 to 14 business days, and if the answer is no the team can try again, for as many as three requests. The plan decides. Our GLP-1 insurance checker explains the process.
Cash prices and coupons
NovoCare is Novo Nordisk’s pharmacy service. It delivers to your home at no charge, and it does not prescribe: a licensed clinician still has to evaluate you and send the prescription.14 There is no coupon for semaglutide as an ingredient, only the separate Wegovy and Ozempic offers. A discount-card price is a cash price, so it cannot be combined with insurance or with the $25 offer.18 Our GoodRx Wegovy guide has the details.
Compounded semaglutide and bundle prices at FitRx
The $151 a month starting price is for the medication alone with a 3-month supply, which ships as three vials in one box. A 1-month supply is also available. The semaglutide bundle combines provider care and compounded semaglutide for $217 the first month and $297 a month after that, and it is refunded under a 30-day guarantee if a provider finds you are not clinically eligible.
A lower price does not make compounded semaglutide a cheaper version of Wegovy. It is not FDA-approved, the FDA does not review it for safety, effectiveness or quality, and it is not a generic of Wegovy or Ozempic. Whether it is appropriate is a provider’s judgment, not a matter of price.8
Compounded semaglutide: what it is, what the FDA says and what to check
The vial pictured at the top of this page is compounded semaglutide.
What compounding is
A compounded drug is prepared by a pharmacy to fill an individual patient’s prescription. The FDA says one might be appropriate if a patient’s medical need cannot be met by an FDA-approved drug, or if the approved drug is not commercially available.8,19
Compounded semaglutide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients. It is not a generic of Wegovy or Ozempic, and it was not the medication tested in any trial on this page.8
Salt forms
The FDA has flagged compounded products made with semaglutide sodium or semaglutide acetate. The agency says these salt forms are different active ingredients, and that it is not aware of a lawful basis for compounding with them.8
Dosing errors
The FDA has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide: patients measuring the wrong dose, and clinicians miscalculating doses. It has also received reports tied to doses beyond the approved label and to raising the dose faster than the label does.20 As of May 31, 2026, the agency had 990 adverse event reports for compounded semaglutide. It notes that such events are underreported and that the cause cannot always be determined.8
Read your prescription label before every dose, and do not raise your dose on your own. If anything about measuring a dose is unclear, message your care team before you inject.
Vials, needles and shipping
The FDA’s advice for injectable GLP-1 medication that comes in a vial:8
- Use a new sterile needle and syringe for each dose.
- Discard a multi-dose vial 28 days after its first use, even if medicine is left in it.
- Do not use it if it arrives warm or without enough refrigeration.
The FDA’s red flags for online sellers
- Claiming that a compounded drug is the same as an FDA-approved drug
- Deep discounts that seem too good to be true
- Medicine that looks different, or arrives damaged or without instructions
- No screening and no prescription from a licensed doctor
- No licensed doctor available afterwards
- Spelling errors on the label, or a wrong pharmacy address
The FDA also says counterfeit Ozempic and products sold “for research purposes” are illegal, and that people should buy only from state-licensed pharmacies.8
How FitRx handles compounded semaglutide
- A U.S.-licensed provider reviews your health history first and decides whether a compounded medication is appropriate. Not everyone qualifies.
- It is prepared by a state-licensed compounding pharmacy. Allow 2 to 7 business days for pharmacy processing, plus 2-day shipping, which is included in the price.
- Your provider stays available after you start, through unlimited secure messaging and monthly video or phone visits.
- We call it what it is: not Wegovy, not Ozempic and not a generic of either.
Other GLP-1 medications, and where to read about each
FitRx providers can prescribe Wegovy, Ozempic, Zepbound or Mounjaro when one of them is appropriate.1,2,10,11 Each has its own page.
| Medication | Active ingredient | FDA-approved for |
|---|---|---|
| Wegovy | Semaglutide | Weight management; cardiovascular risk reduction; MASH (injection) |
| Ozempic | Semaglutide | Type 2 diabetes. Not approved for weight loss. |
| Zepbound | Tirzepatide | Weight management; obstructive sleep apnea with obesity |
| Mounjaro | Tirzepatide | Type 2 diabetes. Not approved for weight loss. |
For the other ingredient as a whole, read the tirzepatide page.

The FitRx care team
No form of semaglutide is prescribed without a provider's review
Semaglutide does not suit everyone. Your intake goes to a U.S.-licensed, board-certified physician or nurse practitioner, who chooses between Wegovy, Ozempic, compounded semaglutide (which is not FDA-approved), another treatment or no medication. FitRx works with licensed providers in all 50 states and DC.
- U.S.-licensed providers review every intake and make every prescribing decision
- Unlimited secure messaging, plus monthly video or phone visits
- A care coordinator and a coach alongside your provider
- An insurance coordination team for brand-name GLP-1 prior authorizations
This page was written and reviewed by the FitRx care team and last updated November 18, 2026. It is general information, not personal medical advice.
Common questions about semaglutide
What is semaglutide, and how is it related to Wegovy and Ozempic?
Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk and the active ingredient in both brands. Wegovy is FDA-approved for weight management, with a recommended maintenance dose of 2.4 mg a week. Ozempic is FDA-approved for type 2 diabetes, with maintenance doses of 0.5 mg, 1 mg or 2 mg a week, and is not approved for weight loss.
Which semaglutide side effects are reported most often?
Nausea, diarrhea, vomiting, constipation and abdominal pain. On the Wegovy label, 44% of adults taking 2.4 mg reported nausea, compared with 16% on placebo. Both brands carry a boxed warning about thyroid C-cell tumors.
When are semaglutide side effects most likely, and how long do they last?
The labels do not give a number of days. What they show is timing: in Ozempic's trials, most nausea, vomiting and diarrhea happened while the dose was being raised. If a step up is hard to tolerate, Wegovy's label allows the next increase to be delayed by 4 weeks, so tell your provider.
Semaglutide vs tirzepatide: which leads to more weight loss?
On average, tirzepatide. SURMOUNT-5 compared the two in 751 adults with obesity and without diabetes. After 72 weeks, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. That is an average, not a forecast for one person.
Is it possible to change from semaglutide to tirzepatide, or back?
Only with your provider. The Zepbound label says tirzepatide is not recommended with any GLP-1 receptor agonist, and semaglutide is one. If a switch makes sense, your provider decides the starting dose and the timing.
What does semaglutide cost with insurance and without it?
As of November 18, 2026, with commercial insurance that covers the brand, Novo Nordisk's savings offers can bring Wegovy or Ozempic to as little as $25 a month. Paying cash, the pens are $199 a month for a new patient's first two fills of 0.25 mg or 0.5 mg, then $349 a month for most doses. Compounded semaglutide through FitRx starts at $151 a month with a 3-month supply and is not FDA-approved. FitRx membership is separate. Confirm current prices before you fill.
Can I get a coupon for semaglutide?
Not for semaglutide as an ingredient. As of November 18, 2026, Wegovy and Ozempic each have a Novo Nordisk savings offer: as little as $25 a month with commercial insurance that covers the brand, with savings limited to $100 a month. People with government coverage are not eligible.
How much weight do people lose on semaglutide?
In STEP 1, adults without diabetes taking brand-name semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo. In STEP 5 the average was 15.2% at two years. Individual results vary.
What happens when you stop taking semaglutide?
In the STEP 1 extension, participants were followed for a year after stopping. They had lost 17.3% of their weight on semaglutide and regained 11.6 percentage points of it, leaving a net loss of 5.6% at week 120. Talk with your provider before you stop.
Does semaglutide come as a pill?
Yes. Wegovy tablets are a once-daily form approved for weight management in adults, with a 25 mg maintenance dose. In the OASIS 4 trial, average weight loss on the 25 mg tablet was 13.6% at 64 weeks, compared with 2.4% on placebo. Ozempic tablets are oral semaglutide for type 2 diabetes only.
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Compounded semaglutide is prepared by a compounding pharmacy for an individual prescription. It is not FDA-approved, the FDA does not review it for safety, effectiveness or quality, and it is not a generic of Wegovy or Ozempic. It was not tested in the trials of those brands. A licensed provider decides whether it is appropriate for you.
Does semaglutide lower the risk of heart attack or stroke?
Wegovy is FDA-approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. In the SELECT trial of 17,604 people followed for about 3 years, such events occurred in 6.5% of those on semaglutide and 8.0% of those on placebo, a hazard ratio of 0.80.
What should I do if I miss a dose of semaglutide?
For the Wegovy injection, if your next scheduled dose is more than 2 days (48 hours) away, take the missed dose as soon as possible. If it is less than 2 days away, skip it. For Ozempic, take the missed dose within 5 days. After that, skip it.
Can I take semaglutide if I am pregnant or planning a pregnancy?
No. Wegovy's label says it may cause fetal harm. For weight management it should be stopped when pregnancy is recognized, and at least 2 months before a planned pregnancy. Ozempic's label also says to stop at least 2 months before a planned pregnancy.
What does FitRx cost, and does it work with insurance?
Membership is $39 for the first month, then $135 a month, and medication is not included. For Wegovy or Ozempic, FitRx's insurance coordination team submits prior authorizations to commercial plans, and you pay for the medication at the pharmacy. FitRx does not work with government insurance, including Medicare, Medicaid and TRICARE.
Important safety information for semaglutide (Wegovy and Ozempic)
Boxed warning: risk of thyroid C-cell tumors. This warning is on both the Wegovy and the Ozempic label. In rodent studies, semaglutide caused thyroid C-cell tumors. Whether it causes them in people, including a cancer called medullary thyroid carcinoma (MTC), is not known. Semaglutide must not be used by anyone with a personal or family history of MTC, or by anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Contact your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.1,2
What Wegovy is for. Wegovy (semaglutide) is used with a reduced-calorie diet and increased physical activity to reduce excess body weight and keep it off in adults with obesity, or with overweight and at least one weight-related condition, and to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. The injection is also approved for children 12 and older with obesity, and for adults with noncirrhotic MASH and moderate to advanced liver fibrosis.1
What Ozempic is for. Ozempic (semaglutide) injection is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes, and to reduce certain cardiovascular and kidney risks in adults with type 2 diabetes who have established cardiovascular disease or chronic kidney disease. Ozempic is not FDA-approved for weight loss.2
Who should not take it. Anyone covered by the boxed warning above, and, for Wegovy, anyone who has had a serious allergic reaction to semaglutide.
Warnings and precautions. Wegovy and Ozempic can cause:
- Inflammation of the pancreas (acute pancreatitis). Get medical help for severe stomach-area pain that will not go away.
- Gallbladder disease, such as gallstones or an inflamed gallbladder.
- Low blood sugar when used with insulin or an insulin secretagogue such as a sulfonylurea.
- Kidney injury when vomiting or diarrhea leads to dehydration.
- Severe stomach and intestinal reactions. Semaglutide is not recommended for people with severe gastroparesis.
- Allergic reactions that can be serious, such as anaphylaxis and angioedema.
- Diabetic retinopathy complications in people with type 2 diabetes or a history of diabetic retinopathy.
- An increase in heart rate (listed on the Wegovy label).
- Pulmonary aspiration (stomach contents entering the lungs) under general anesthesia or deep sedation.
Never share an Ozempic pen or a Wegovy FlexTouch pen with another person.
Most common side effects. Wegovy (5% or more of people): nausea, diarrhea, vomiting, constipation, abdominal pain, altered skin sensation, headache, fatigue, indigestion, dizziness, bloating, belching, low blood sugar in people with type 2 diabetes, gas, gastroenteritis, gastroesophageal reflux disease and hair loss. Ozempic (5% or more): nausea, vomiting, diarrhea, abdominal pain and constipation.
Pregnancy and breastfeeding. Wegovy may cause fetal harm. When it is used for weight reduction or cardiovascular risk reduction, stop it when pregnancy is recognized and at least 2 months before a planned pregnancy. Stop Ozempic at least 2 months before a planned pregnancy. Breastfeeding is not recommended during treatment with Wegovy tablets.
Other medicines. Because semaglutide slows the emptying of the stomach, it can change the absorption of medicines you swallow. Give your provider a full list of what you take.
This summary does not replace the full prescribing information or a conversation with your provider. To report a side effect to the FDA, go to www.fda.gov/medwatch or call 1-800-FDA-1088.
About compounded semaglutide. Compounded semaglutide is not FDA-approved, and the FDA does not check compounded drugs for safety, effectiveness or quality before they are dispensed. It is not a generic of Wegovy or Ozempic, and it was not part of the clinical trials behind those brands. Whether a compounded medication is appropriate is a licensed provider’s decision.8
Find out what a provider recommends for you
Start with the online intake. A licensed provider typically reads it within 1 to 2 business days and tells you whether any form of semaglutide is appropriate.
Get startedFitRx membership costs $39 in month one and $135 a month from then on. Medication is a separate charge. Not everyone qualifies.
References (20)
- Wegovy (semaglutide) injection and tablets. Prescribing information. Novo Nordisk; revised June 2026. https://www.novo-pi.com/wegovy.pdf
- Ozempic (semaglutide) injection. Prescribing information. Novo Nordisk; revised May 2026. https://www.novo-pi.com/ozempic.pdf
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. https://pubmed.ncbi.nlm.nih.gov/36216945/
- Wharton S, Freitas P, Hjelmesaeth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;13(11):949-963. https://pubmed.ncbi.nlm.nih.gov/40961952/
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. https://pubmed.ncbi.nlm.nih.gov/29617641/
- Rybelsus and Ozempic (semaglutide) tablets. Prescribing information. Novo Nordisk; revised January 2026. https://www.novo-pi.com/ozempictablets.pdf
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
- Zepbound (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf
- Mounjaro (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
- Novo Nordisk. NovoCare: Wegovy list price, savings offer and self-pay prices. https://www.novocare.com/patient/medicines/wegovy.html
- Novo Nordisk. NovoCare: Ozempic savings offer and list price. https://www.novocare.com/diabetes/products/ozempic/savings-offer.html
- Novo Nordisk. Save on Ozempic: savings offer, self-pay prices and Medicare information. https://www.ozempic.com/savings-and-resources/save-on-ozempic.html
- Medicare.gov. Weight loss drugs and the Medicare GLP-1 Bridge. https://www.medicare.gov/coverage/weight-loss-drugs
- GoodRx. How much does Wegovy cost without insurance? Wegovy prices, coupons and savings. https://www.goodrx.com/wegovy/wegovy-for-weight-loss-cost-coverage
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
Sources were opened and checked on November 18, 2026. Prices, savings programs and labels change; confirm current terms with the manufacturer, your pharmacy or your provider.